Evidence map›Paper›PMID 25646469›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.

Andrea Björkman, Per Qvist, Likun Du, Margarita Bartish, Apostolos Zaravinos, Konstantinos Georgiou, Anders D Børglum, Richard A Gatti, Therese Törngren, Qiang Pan-Hammarström

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Andrea BjörkmanDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden;
Per QvistDepartment of Biomedicine and Centre for Integrative Sequencing, Aarhus University, 8000 Aarhus, Denmark;
Likun DuDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden;
Margarita BartishDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden;
Apostolos ZaravinosDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden;
Konstantinos GeorgiouDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden;
Anders D BørglumDepartment of Biomedicine and Centre for Integrative Sequencing, Aarhus University, 8000 Aarhus, Denmark;
Richard A GattiDepartments of Pathology and Laboratory Medicine and Human Genetics, University of California, Los Angeles, CA 90095; and.
Therese TörngrenDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund 22100, Sweden.
Qiang Pan-HammarströmDepartment of Laboratory Medicine, Karolinska Institutet, 141 86 Stockholm, Sweden; qiang.pan-hammarstrom@ki.se.
Karolinska Institutet · SEAarhus University · DKLund University · SEUniversity of California, Los Angeles · US

Funding

European Research Council 242551
6 · The paper itself

Abstract

Breast cancer type 1 susceptibility protein (BRCA1) has a multitude of functions that contribute to genome integrity and tumor suppression. Its participation in the repair of DNA double-strand breaks (DSBs) during homologous recombination (HR) is well recognized, whereas its involvement in the second major DSB repair pathway, nonhomologous end-joining (NHEJ), remains controversial. Here we have studied the role of BRCA1 in the repair of DSBs in switch (S) regions during immunoglobulin class switch recombination, a physiological, deletion/recombination process that relies on the classical NHEJ machinery. A shift to the use of microhomology-based, alternative end-joining (A-EJ) and increased frequencies of intra-S region deletions as well as insertions of inverted S sequences were observed at the recombination junctions amplified from BRCA1-deficient human B cells. Furthermore, increased use of long microhomologies was found at recombination junctions derived from E3 ubiquitin-protein ligase RNF168-deficient, Fanconi anemia group J protein (FACJ, BRIP1)-deficient, or DNA endonuclease RBBP8 (CtIP)-compromised cells, whereas an increased frequency of S-region inversions was observed in breast cancer type 2 susceptibility protein (BRCA2)-deficient cells. Thus, BRCA1, together with its interaction partners, seems to play an important role in repairing DSBs generated during class switch recombination by promoting the classical NHEJ pathway. This may not only provide a general mechanism underlying BRCA1's function in maintaining genome stability and tumor suppression but may also point to a previously unrecognized role of BRCA1 in B-cell lymphomagenesis.

Indexed as

DNA RepairImmunoglobulin Class SwitchingRecombination, GeneticB-LymphocytesBRCA1 ProteinHumansBRCA1 ProteinBRCA1 protein, humanalternative end-joiningB cellsBRCA1immunoglobulin class switch recombinationnonhomologous end-joining

Identifiers

PMID25646469
PMCPMC4343177
OpenAlexW2142360126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.